Solventum Corporation

SOLV Healthcare Medical Instruments & Supplies

Solventum Corporation’s revenue for fiscal 2025 (year ended December 2025) was $8.3 billion, up 0.86% from fiscal 2024.

Revenue
−7.01%
EPS
−101.0%
Free cash flow
+561.9%
Total debt
−90.1%

Quarter to September 2026, against a year earlier

91.28 4.10 +4.70%
Market cap
$14.8B
P/E
97.3×
Fwd P/E
47.7×
Dividend yield
—
F-score
5/9
Altman Z
2.22
Beneish M
−2.07
Dividend safety
n/a

Solventum Corporation 10-Q filed Nov 5, 2026

Fiscal Q3 2026 · Period ended Sep 30, 2026 · Filed · accepted 5:17 PM ET · Document on sec.gov · Filing index

Red flags

What changed

Part II, Item 1A, Risk Factors, against the 10-Q filed Aug 5, 2026: 6 added · 2 modified